Ryan Sessegnon has become the latest footballer to reveal he has received racist abuse on social media.Sessegnon received the abusive messages on Monday night, shortly before the offending profile was removed from Instagram.- Advertisement – Everyone at the Club is with you @RyanSessegnon. We are proud of the rich ethnic diversity that exists across our communities, fans, staff and players. We are driven by inclusion and equality for all and nobody should have to endure such repulsive abuse. pic.twitter.com/Tliv3rdRtI— Tottenham Hotspur (@SpursOfficial) November 3, 2020 His parent club have since offered their support on Twitter.“Everyone at the Club is with you Ryan Sessegnon,” Tottenham’s official Twitter account said.“We are proud of the rich ethnic diversity that exists across our communities, fans, staff and players.- Advertisement – – Advertisement – “We are driven by inclusion and equality for all and nobody should have to endure such repulsive abuse.”The England Under-21 international moved to Tottenham from Fulham for £25m in the summer of 2019, but was allowed to seal a temporary move away from the club following Sergio Reguilon’s arrival. In July, Crystal Palace’s Zaha called for ‘action and education’ and after he too was subjected to racist messages before a match against Aston Villa. – Advertisement – He has now joined the likes of fellow footballers Raheem Sterling, Wilfried Zaha and Troy Deeney who have also spoken out about the racist and threatening abuse they have received on social media.Last month, Watford’s Deeney openly questioned whether social media companies have the desire to eradicate abuse and argued they may even benefit from a drive in traffic when incidences of racism occur. Image:Wilfried Zaha called for greater action and education after he received racist messages in July The 20-year-old was left disgusted by the abuse but said he is not surprised that it continues to take place.He wrote on Instagram: “Honestly unbelievable. The craziest thing is I’m not even surprised anymore. Disgusting.”Sessegnon has so far featured four times on loan at Bundesliga side Hoffenheim, after sealing a season-long loan switch from Tottenham last month. Image:Sessegnon in Europa League action for Hoffenheim
Live From The Masters November 9, 2020, 7:00pmLive on Get the best prices and book a round at one of 1,700 courses across the UK & Ireland Watch highlights from the final round of the Houston Open at Memorial Park 3:33 Watch highlights from the final round of the Houston Open at Memorial Park Carlos Ortiz won his first PGA Tour title at the Houston Open after holding off strong challenges from Dustin Johnson and Hideki Matsuyama.A birdie at 16 proved crucial for Ortiz as he moved one clear of world No 1 Johnson and Matsuyama, who surged into contention with a course-record 63.Johnson and Matsuyama missed putts to join Ortiz on 12-under par and the Mexican sealed victory with a birdie at the last to win by two shots and earn himself a place at the 2021 Masters.The world No 149 is not on the entry list at Augusta this week, but Johnson and Matsuyama demonstrated they are both likely to be among the contenders for the final major of 2021.Matsuyama was one of three players – along with Mackenzie Hughes and Talor Gooch – to shoot a 63 on the last day while Johnson put pressure on Ortiz until the last. However, the Mexican kept his composure to win the biggest title of his career.“It feels awesome,” he said. “It’s been a while since I have won – it feels good. – Advertisement – – Advertisement – – Advertisement – Back-to-back bogeys on 10 and 11 hurt Lowry’s chances, but Johnson continued his challenge by holing a 60-foot putt for birdie at the 11th and Matsuyama moved into contention with successive birdies at 12 and 13.As Koepka slipped with bogeys on 14 and 17, it was Johnson who looked the most likely to topple Ortiz and a first birdie of the week at 15 saw the American move into a share of the lead.Ortiz missed a fantastic eagle chance at 16, but tapped in from close range to move back in front just as Matsuyama recorded another birdie to move to 11-under par.Johnson and Matsuyama both missed chances to move to 12 under and Ortiz not only held his nerve on the final hole but holed a birdie putt to win by two shots. The 29-year-old finished on 13-under par, two shots ahead of Dustin Johnson and Hideki Matsuyama, to win the biggest title of his career. He is not on the entry list for next week’s Masters but has secured an invitation for the major in 2021. Last Updated: 08/11/20 11:14pm “I made some huge putts on the front nine, that kickstarted my round, and after that I played really good, I didn’t miss many shots, and it was awesome finishing with the birdie on 18.”Gooch finished fourth, one shot ahead of Brooks Koepka, who finished with back-to-back rounds of 65, and Sepp Straka.Sam Burns started the final day with a one-shot lead but quickly saw his position at the top of the leaderboard under threat.
– Advertisement – Right now, Trump’s team is 0-12 for the court cases they’ve brought in half a dozen states. Because not only do they have no evidence, they also have no particular intention of winning. It’s all for show.What it’s about is raking in millions for Trump. Not only does the money being brought in pay Rudy Giuliani to stand in front of landscaping stores and spread lies, the money is also being used to pay down debts Trump ran up during the campaign. In the case of solicitations from the “Make America Great Again Committee,” exactly none of the money goes to actual investigation of the fraud they know never happened. Instead, 40% of the money goes to the RNC while 60% flows to Trump’s campaign. Just as he did with his inaugural fund in 2016, Trump has turned “election defense” into a way to not only take in cash, but to take in cash in quantities not limited by laws about election contributions. Donors to the MAGA committee or Save America PAC aren’t going to hit the wall of campaign contributions … even though most of the money is going to end up in Trump’s campaign, where he can turn around and pay his family, friends, and self any amount he wants. It is a cash grab, pure and simple.- Advertisement – But why would other Republicans be going along with this? Well, this maneuver from South Dakota Gov. Kristi Noem provides a good clue. In an online solicitation, Noem urges voters to “help us bring it home for the president” and warns that Trump “needs our support while the far-left Dems declare a victory for Biden before all the votes are counted.” However, none of the money going into this fund is connected with funding investigations into campaign fraud. It’s not even going to Trump’s campaign. 100% of the donations instead flow into Noem’s own reelection fund.Whether Trump ever calls Biden, or whether he prefers to pretend to be the prince in exile, forever fighting against an usurper who took his rightful place will be determined by the same thing that’s driving his strategy, and the strategy of other Republicans right now: the money. There really is election fraud. And Donald Trump, along with 99% of the nation’s Republican leadership, are engaged in it at the moment. As The Washington Post reports, all but a handful of Republicans aren’t just echoing Trump’s claims about nonexistent voter fraud, they’re doing so while fully aware that their actions are both damaging faith in the democratic process and preventing President-elect Biden from having access to national security information and other classified documents that could be vital to planning his transition. Republicans obviously want to show that they’re still loyal to Trump—in the case of those like Sen. Lindsey Graham, disgustingly so. But Trump hasn’t exactly made it a secret what this is about. From the night of the election, Trump supporters have been receiving emails asking them to donate to the “Official Election Defense Fund” or the new “Save America PAC.” Some supporters report that they have received up to 18 solicitations in a single day asking for money for one or both of these projects.Trump voters are being told that these funds are going to support an “emergency recount” of votes in Wisconsin. Or that they are being used to present “proof” of voter fraud in court. Only Trump’s campaign has not actually asked for a recount in Wisconsin, much less ponied up the $3 million that’s required. And it’s certainly not what Trump’s actual attorneys are saying in actual courts.Judge: Are you claiming that there is any fraud in connection with these 592 disputed ballots?Trump attorney: To my knowledge at present, no.Judge: Are you claiming there is any undue or improper influence upon the elector with respect to these 592 ballots?Trump attorney: To my knowledge at present, no.- Advertisement – Donald Trump’s refusal to concede has absolutely nothing to do with winning the election. No matter what Trump may be tweeting from the Fortress of Poutitude, he knows he’s lost. There is no scenario in which recounts and court challenges are going to uncover anything close to enough votes to overcome the clear result of the election. The refusal to place that grudging call to Joe Biden is also not being set by Trump’s ego. Of course that ego is a factor. Since it’s the size of a small moon, Trump’s ego always generates enough gravity to distort any situation, but no matter how many pundits pearl-clutch over giving Trump time to adjust to being a big loser, or how many Republicans show that they’re so there for Trump in his hour of despair, that’s just … not it. The biggest reason that Donald Trump won’t concede is the simplest. It’s the same reason that has driven every decision of Trump’s life: money.- Advertisement –
Oct 12, 2004 (CIDRAP News) – To cope with the loss of nearly half of the nation’s influenza vaccine supply, federal health officials and Aventis Pasteur announced plans today to distribute Aventis’s 22.4 million remaining doses to those who need them the most.”Beginning immediately, about 14.2 million doses of vaccine will be allocated over the next 6-8 weeks through Aventis Pasteur contracts directly to high-priority vaccine providers, including hospitals, long-term care facilities, nursing homes, and private providers who care for young children,” the Centers for Disease Control and Prevention (CDC) said in a news release.In a second phase later, about 8.2 million doses will be shipped to “other high-need areas,” the CDC said. “This plan will help ensure that vaccine gets to those people who need it the most,” CDC Director Julie Gerberding, MD, MPH, said in the release.The plan follows last week’s announcement that about 48 million doses of flu vaccine from Chiron Corp. will not be available this year. The British government shut down Chiron’s plant in Liverpool last week and stopped the shipment of doses to the United States because of contamination problems in the plant. The Chiron vaccine would have constituted nearly half of the projected US supply of 100 million doses this year.Last week the CDC recommended that healthy people from ages 2 through 64 not get flu shots so that the available doses can be saved for the high-risk groups, including the elderly, babies aged 6 to 23 months, people living in nursing homes and long-term care facilities, people with chronic medical conditions, pregnant women, children on chronic aspirin therapy, and healthcare workers directly caring for patients.In a news briefing today, Gerberding said the CDC estimates that between 42 million and 50 million people are in the high-risk groups and will request vaccine. “This year we won’t be able to get vaccine to all of them. . . . There may be some people who may not be able to get vaccine who really need it.”Because of the shortage, she urged people to take normal precautions against flu and to seek treatment immediately if they get sick. She said the CDC is stockpiling antiviral drugs such as oseltamivir (Tamiflu) in the hope of using them to blunt the effects of the vaccine shortage.”We’re sorry that people who want vaccine may not be able to get it. We appreciate everyone’s help in pulling this together,” Gerberding said.Also in the news briefing, Aventis Pasteur US President Damian Braga said about 15 million of the company’s 22.4 million remaining doses have been committed to customers. Of those 15 million, 11.8 million were already scheduled to go to high-risk customers, he said. “We’re hoping that with some cooperation from our customers, the actual disruption to our customers will be at a minimum,” he added. The company has produced a total of 55.4 million doses this year, he said.Gerberding said the CDC is “working aggressively to map out where influenza is by county” and also mapping the delivery of doses and need for vaccine by county. “So what we’ll end up with in a few days is a comprehensive picture of who needs vaccine and where it is,” she said.Gerberding said the CDC is relying on the “honor code” to enforce compliance with the recommendation that vaccine doses be saved for people in high-risk groups. This has worked in the past, and “so far we have good evidence that it’s working this time too,” she added.She noted that a Food and Drug Administration (FDA) team is still in Britain checking to see “if there are any safe doses of vaccine that can be acquired from Chiron at this time.”In other developments, the pharmaceutical company GlaxoSmithKline (GSK) said yesterday it was exploring the possibility of selling its Fluarix flu vaccine in the United States, according to a Reuters report. The vaccine is sold in 70 countries but not in the United States, because the company decided in 1992, when it launched the product, that the US market was overcrowded.A GSK official told Reuters that the company was talking with the FDA about the possibility of getting approval for the sale of Fluarix this season. But most of the company’s supply is already committed to other customers, leaving only around 200,000 doses available for new buyers, the report said.See also:Oct 12 CDC news releasehttp://www.cdc.gov/media/pressrel/r041012.htm
Mar 25, 2005 (CIDRAP News) – Two new studies give reason to hope that vaccines prepared in advance could be of some help in combating an influenza pandemic.A flu pandemic can occur when a flu virus undergoes a significant change in its surface proteins, making it unrecognizable to the immune system. Because such “antigenic shifts” are unpredictable, it is not possible to design a vaccine to precisely match a pandemic flu virus until the virus emerges.Disease experts fear that the H5N1 avian influenza virus, which has become endemic in poultry in Southeast Asia, may trigger a human flu pandemic if it acquires the ability to spread readily from person to person. This week the United States launched the first clinical trial of a vaccine for the H5N1 virus. But there is no guarantee that the vaccine would work if a pandemic erupted, since a change in the virus would probably precede that development.However, two studies recently published online by the Journal of Infectious Diseases suggest that avian flu vaccines that don’t match up perfectly with the viruses they are intended for may provide some protection.In one study, human volunteers received a vaccine made from a nonpathogenic H5N3 virus isolated from ducks. When H5N1 viruses were added to serum samples from the volunteers, a significant immune response was generated in the form of antibodies.In the other experiment, mice were given one of two vaccines that contained surface proteins from H5N1 viruses isolated from geese and humans. When the mice were subsequently exposed to other H5N1 viral strains, the vaccines protected most of them from dying or getting sick.Immune response in human serumThe human study was conducted by a team of researchers from the Centers for Disease Control and Prevention, Chiron Vaccines in Italy, and two laboratories in the United Kingdom. They recruited 65 people in Leicester, UK, and gave them two doses of a vaccine made from an H5N3 duck virus isolated in Singapore in 1997. Some of the volunteers received the vaccine alone, while others received the vaccine with an adjuvant—a compound that helps stimulate immune responses—called MF59. Sixteen months later, 26 of the 65 volunteers received a third dose of the same vaccine they had received before (15 received vaccine with MF59, while 11 received vaccine with no adjuvant).Serum samples were taken before and 3 weeks after vaccination and sent to the CDC, where they were tested for antibody responses to four different H5N1 viruses isolated from humans. These included 1997 and 2003 strains from Hong Kong and 2004 strains from Vietnam and Thailand.The experiment showed that the conventional (no adjuvant) vaccine induced little antibody response to any of the H5N1 viruses, whereas the adjuvanted vaccine generated good responses.After three doses of adjuvanted vaccine, significant antibody responses (seroconversion) to the Hong Kong 1997 virus were seen in 100% of the samples. Seroconversion rates for the other three viruses were 100% for Hong Kong 2003, 71% for Thailand 2004, and 43% for Vietnam 2004. The seroconversion rates for the nonadjuvanted vaccine with respect to the four viruses were 27%, 27%, 0%, and 0%.The researchers write that three doses of the adjuvanted vaccine “induced broadly cross-reactive antibody capable of neutralizing antigenically distinct HPAI [highly pathogenic avian influenza] H5N1 viruses isolated from humans during 1997-2004. . . . The ability of an H5 vaccine to induce broad cross-reactive immune responses could be crucially important in the early response to an emerging pandemic.”The authors acknowledge that a three-dose immunization schedule wouldn’t be practical in the face of a pandemic. However, they suggest that in the early stages of a pandemic it may be possible to provide partial protection for people at high risk, such as healthcare workers, with an adjuvanted vaccine made from an H5 virus strain prepared in advance.Vaccines protect miceThe mouse experiment was conducted by Aleksandr S. Lipatov and four colleagues at St. Jude’s Children’s Research Hospital in Memphis. They injected mice with one of two inactivated vaccines made with the process called reverse genetics. The researchers used genes for the surface proteins—hemagglutinin and neuraminidase (HA and NA)—and internal proteins from several different flu viruses.One vaccine, called delta H5N3, combined the HA gene from a 1999 H5N1 goose virus from Hong Kong with the NA gene from an H2N3 duck virus from Germany. The other vaccine, called delta H5N1/03, used the HA and NA genes from a human H5N1 virus isolated in Hong Kong in 2003. Both vaccines also contained six viral genes encoding internal proteins from an H1N1 virus, along with an adjuvant.After immunization at one of three doses of vaccine, the mice were exposed to one of three H5N1 viruses: human isolates from 1997 and 2003 and an avian virus from 2001. The vaccinated mice responded with high levels of antibodies, which in most cases decreased or prevented viral replication in their lungs.From 90% to 100% of mice injected with the delta H5N3 vaccine survived and had few signs of illness, whereas all of the control mice died. The delta H5N1/03 vaccine provided nearly as high a level of protection. The exception was that mice that received the lowest dose of vaccine were vulnerable to the 2001 avian H5N1 virus.The authors also analyzed and found slight differences among the amino acid sequences of the HAs in the two tested vaccines and the three challenge viruses. They conclude, “The present results demonstrate the cross-protective efficacy of H5N1 vaccine viruses that contain antigenically different HAs. Our data suggest that, at least in the mouse model, the vaccine strain need not match the challenge virus to achieve a high level of cross-protection.”In an editorial accompanying the two reports, Benjamin Schwartz and Bruce Gellin of the Department of Health and Human Services’ (HHS’) National Vaccine Program Office welcome the studies but cite various limitations. The studies “do provide a good foundation for further work to develop and test candidate pandemic vaccines and assess pandemic vaccination strategies,” they write.Concerning the human study, Schwartz and Gellin state, “The need for 3 vaccine doses, the use of an adjuvant not licensed in the United States, and uncertain levels of protection even in a young and healthy population limit the viability of such a vaccination strategy.”The mouse experiment provides “proof of concept that H5 vaccines produced by use of reverse genetics can be immunogenic and effective in an animal model,” Schwartz and Gellin say. “However, no conclusions can be reached regarding levels of protection in humans, the number of doses needed, the amount of antigen required per dose, the need for an adjuvant, or the degree of protection against all heterologous H5 strains.”Stephenson I, Burgarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005 Apr 15 ;191(8):1210-5 [Abstract]Lipatov AS, Webby RJ, Govorkova EA, et al. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005(Apr 15);191(8):1216-20 Vaccination strategies for an influenza pandemic. J Infect Dis 2005 Apr 15 ;191(8):1216-20 [Abstract]Schwartz B, Gellin B, et al. Vaccination strategies for an influenza pandemic. (Editorial Commentary) J Infect Dis 2005 Apr 15 ;191(8):1207-9 [Full text]
Feb 27, 2006 (CIDRAP News) – A girl and a young woman in China have contracted avian influenza and are in critical condition, marking the 13th and 14th confirmed cases there, the World Health Organization (WHO) reported today.In addition, the WHO recognized a fatal human case of avian flu that was reported last week in Indonesia. The WHO’s current global count of human bird flu cases is 173, including 93 deaths.The patients in China are a 9-year-old girl from the eastern province of Zhejiang and a 26-year-old female farmer from the adjoining Anhui province, according to the WHO.The girl became ill on Feb 10 after she visited relatives in Anhui, the WHO said. No animal outbreaks have been reported in Zhejiang since 2004.The Chinese news agency Xinhua reported that during the girl’s visits with relatives, chickens in the relatives’ households got sick, and some died.The WHO said the farmer had had contact with diseased poultry before she fell ill Feb 11. Local agricultural officials reported that the H5N1 virus was found in dead poultry in her neighborhood.Samples from both patients tested positive in provincial laboratories and China’s national disease-control laboratory, according to Xinhua.”The H5N1 virus is now considered to be endemic in birds in large parts of China,” the WHO said.Of the 14 total cases in China, 8 have been fatal.The latest fatal case in Indonesia involved a 27-year-old woman from West Java province who fell ill Feb 13 and died a week later, the WHO said. Indonesian authorities reported last week that she had tested positive in a local lab.Including this case, Indonesia has had 27 cases with 20 deaths.See also:WHO statement on cases in Chinahttp://www.who.int/csr/don/2006_02_27a/en/index.htmlWHO statement on case in Indonesiahttp://www.who.int/csr/don/2006_02_27/en/index.html
May 12, 2006 (CIDRAP News) – An analysis of more than 600 H5N1 avian influenza viruses collected from several Asian countries suggests that two older antiviral drugs could be more useful in fighting a flu pandemic triggered by H5N1 than previously believed.Most H5N1 viruses collected from humans and poultry in Vietnam and Thailand have been resistant to the two older drugs, amantadine and rimantadine (known as the adamantanes). As a result, hopes for an effective drug have focused on the newer antivirals, oseltamivir and zanamavir. Many countries have been stockpiling oseltamivir.But an international team of scientists is reporting that resistance to amantadine seems less common than has been believed, at least in some countries. As expected, they found that most viruses from Vietnam, Thailand, and Cambodia had mutations that signaled resistance to amantadine. But only a few of the viruses from China and Indonesia had those mutations.”Amantadine appears to retain the potential to be useful in an H5N1 pandemic in the absence of a vaccine, as a prophylactic agent and as a component of combination antiviral therapy,” says the report, published online by the Journal of Infectious Diseases.The study was done by scientists from the University of Hong Kong; Shantou University in Guangdong, China; St. Jude Children’s Research Hospital in Memphis, Tenn.; and the Center for Indonesian Veterinary Studies in Jakarta. Chung Lam-Cheung of the University of Hong Kong was the first author.The researchers analyzed the genetic sequences of the M2 ion channel protein of 638 H5N1 viruses, including 599 from birds and 39 from humans. Most of the isolates came from Hong Kong, China, Vietnam, Thailand, and Indonesia, with a few from Cambodia, Malaysia, Japan, and Korea. The sequences were screened for four mutations predicted to confer amantadine resistance.Tabular data in the report show that 92.6% (162 of 175) of the Vietnam isolates had resistance mutations, as did all the isolates from Thailand (58 of 58), Cambodia (9 of 9), and Malaysia (2 of 2). In contrast, only 13% (16 of 123) of the isolates from China and 6.3% (2 of 32) of those from Indonesia had such mutations. None of the eight isolates from Japan and Korea, collected from poultry in late 2003, showed resistance.”Although amantadine-resistant H5N1 viruses are present in Asia, their distribution appears to be largely limited to Thailand, Vietnam, and Cambodia,” the report states. In an apparent reference to reports of amantadine use in poultry in China, the authors add, “That most H5N1 isolates from China and Indonesia are sensitive to amantadine is striking and perhaps surprising, in view of the reportedly widespread administration of amantadine to farmed poultry in some countries.”Amantadine and rimantadine have been used in treating human flu for more than a decade. However, flu viruses can quickly become resistant to the drugs, because just one point mutation is required. Last January, the Centers for Disease Control and Prevention advised physicians to stop prescribing the drugs for the rest of the flu season because the predominant strain of influenza A had turned highly resistant to them. The resistance rate in the H3N2 strain had soared to 91%, compared with 11% the year before.Cheung C-L, Rayner JM, Smith GJD, et al. Distributionof amantadine-resistantH5N1avianinfluenzavariants in Asia. J Infect Dis 2006 Jun 15;193(12):1626-9 [Full text]See also:CIDRAP information on the use of antiviral drugs in a flu pandemic
Mar 24, 2009 – The annual meeting of the Society for Healthcare Epidemiology of America took place Mar 20-22 in San Diego. This News Scan Special Edition wraps up interesting research from that meeting on the difficult problem of increasing influenza immunization in healthcare workers. Lip-sync video makes case to healthcare workers for flu shotsUniversity of Pennsylvania Medical Center struggled to raise the rate of healthcare workers accepting annual flu shots, even with a 2-year-old “opt-out” program accompanied by mandatory education programs for those who refused. This year, though, flu-shot acceptance has risen 40%. What turned the tide was a home-grown music video, running on the hospital’s intranet and patient TV, that features healthcare workers lip-syncing to “Baby Be Wise—Immunize,” recorded by Penn’s undergraduate a capella group, Penn Yo.[YouTube video] 50-hospital survey finds commonalities in diverse flu-shot programsA nationwide survey conducted by researchers at Vanderbilt University School of Medicine in Nashville, Harborview Medical Center in Seattle, University of Maryland Medical Center in Baltimore, and the University HealthSystem Consortium in Oak Brook, Ill., found that programs to increase flu shots in hospitals vary regarding which employees they target and what strategies they use. However, the most successful programs had strong visible support from hospital leadership and provided after-hours and weekend access to vaccine. Unvaccinated healthcare workers highly vulnerable to fluFinally, a Canadian national survey suggested the potential risks to healthcare workers and their patients when workers are not vaccinated. A survey of healthcare workers in Toronto during the 2007-08 season, when the vaccine was poorly protective, demonstrated that 20% contracted flu. Moreover, 92% worked on the first day of their illness and 85% worked on every day that they were ill, increasing the risk of passing the disease to vulnerable patients. Strict medical or religious exemption policy raised ratesWashington University School of Medicine and healthcare organization BJC HealthCare increased vaccination rates among workers by making flu shots a condition of employment unless the employee could show proof of medical or religious necessity. Employees claiming religious exemption were required to write a letter to human resources; employees claiming medical exemption, such as prior hypersensitivity to flu vaccine or to the eggs in which it is made, were required to present a letter from a physician. Employees who were not vaccinated and could not prove exemption were terminated. Vaccination rates rose to 98.4%. ‘Push-pull’ campaign inspired by bioterror response plans increases vaccinationFlushing Hospital Medical Center outside New York City almost doubled healthcare workers’ willingness to take flu shots by deploying a persuasion strategy borrowed from mass-disaster planning. The technique, called “push-pull,” starts with intensive education on every hospital unit; personnel who either accepted the shot or signed a form declining it were given an ID-validating sticker for their badges. The following day, all employees were directed to a single hospital entrance, and those without stickers were steered to a vaccination team for a second go-round. Vaccination rose from 38% of staff to 60%.
In the Official Gazette No. 61/2017. as of June 28, 2017, changes to the following laws / regulations have been published:RULEBOOK ON AMENDMENTS TO THE RULEBOOK ON DECLARATION OF TOURIST MUNICIPALITIES AND TOWNS AND ON THE CLASSIFICATION OF SETTLEMENTS IN TOURIST CLASSESRULEBOOK ON CRITERIA AND MANNER OF USING DONATIONS AND OWN REVENUES OF NATIONAL PARKS AND NATURE PARKSDECISION ON PROMULGATION OF THE LAW ON CONCESSIONSRULEBOOK ON AMENDMENTS TO THE RULEBOOK ON CLASSIFICATION AND CATEGORIZATION OF FACILITIES IN WHICH CATERING SERVICES ARE PROVIDED ON A FAMILY AGRICULTURAL HOLDINGRULEBOOK ON AMENDMENTS TO THE RULEBOOK ON CLASSIFICATION AND CATEGORIZATION OF CATERING FACILITIES FROM THE GROUP OTHER CATERING FACILITIES FOR ACCOMMODATIONRULEBOOK ON AMENDMENTS TO THE RULEBOOK ON CLASSIFICATION AND CATEGORIZATION OF FACILITIES IN WHICH HOUSEHOLD CATERING SERVICES ARE PROVIDED
12 Croatian accommodation facilities entered the finals of the selection for the best tourist apartment or holiday home in Europe called the European Holiday Home Award. The solemn announcement of the winners will be at a gala dinner on September 14, organized by the European Family Tourism Association EHHA, of which the Family Tourism Association of the Croatian Chamber of Commerce has been a member since March.”This success of accommodation facilities from Croatia is a confirmation of the work of the Family Tourism Association at the Croatian Chamber of Commerce on improving quality by promoting specialization, branding and education developed through the annual cycle of national and cluster Family Accommodation Forums through which more than 6000 family accommodation hosts are educated ”, commented the president of the Family Tourism Association at the Croatian Chamber of Commerce, Nedo Pinezić.The categories in which it was possible to compete are the best holiday accommodation in the European capital, the best beach holiday accommodation, the best family holiday accommodation, the best green holiday accommodation, the best pet holiday accommodation, the best health and wellness holiday accommodation , the best unique vacation spot and the best affordable vacation accommodation. They are nominated from Croatia Villa Vista Zamask, apartmani Peljesac-Sreser, House for rest Verudica, Villa Sea Edge, Holiday Villa in Split, Villa Falcon Rook, Makarska-Gornje Podbablje, Villa Milica, Villa Prosika, Split-Srinjine, Zminj-Vadediji House Ulika.Family accommodation in Croatia confirmed the quality on the European marketAfter the first phase, the expert jury selected eight finalists for each category, including as many as 12 from Croatia, or at least one in each of the categories. “A total of 425 accommodation facilities from 18 countries were registered with a total of 640 nominations. Most applications by country came, after Spain, from Croatia, more precisely from Istria and Dalmatia, and the management is from those regions and finalists”, Said the vice president of the Family Tourism Association at the Croatian Chamber of Commerce Danijela Cavlovic, which is also a member of the Evaluation Committee of the European Holiday Home Award.The Croatian Chamber of Commerce reminds that in September, applications for the awarding of prizes for family accommodation within the action “Tourist flower – Quality for Croatia” will be opened, and applications will be able to be sent via the form that will be published next week on website-pages of the Croatian Chamber of Commerce.